A phase II trial of huperzine A in mild to moderate Alzheimer disease
Rafii MS, Walsh S, Little JT, Behan K, Reynolds B, Ward C, Jin S, Thomas R, Aisen PS
Published in Neurology
Methodology
Sixteen-week randomised double-blind placebo-controlled multicentre US trial of huperzine A 200 or 400 micrograms twice daily in mild to moderate Alzheimer disease
Key Findings
The primary outcome, change in ADAS-Cog at week 16, did not differ from placebo at 200 micrograms twice daily; a possible signal at the higher dose was a secondary finding only.
Conclusions
A rigorously conducted US trial failed to confirm the cognitive benefit reported in earlier Chinese studies.
Limitations
Modest sample size; 16-week duration; higher dose underpowered.
Supplements Studied
The primary outcome, change in ADAS-Cog at week 16, did not differ from placebo.
Outcomes Measured
Change in ADAS-Cog at week 16 did not differ from placebo.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.